On 12 August 2025, Celltrion announced that it has been awarded a series of supply contracts in Italy for its autoimmune disease therapies and oncology treatments. Key contracts include additional contracts for Steqeyma®, biosimilar to J&J/Janssen’s Stelara® (ustekinumab), in the Veneto, Trentino-Alto Adige, and Sardinia regions, following contracts for four regions earlier this year. This means that Celltrion will now supply Steqeyma® to seven regions in total through to May 2026.
Steqeyma® was approved in Europe in August 2024, following a positive CHMP opinion in June 2024. Celltrion launched Steqeyma® in Italy in mid-January 2025, with Celltrion confirming on 23 January 2025 that it had completed the launch of Steqeyma® in Italy, France, Spain, the UK, and Germany. Celltrion was the third company to launch an ustekinumab biosimilar in Europe.
On 22 July 2024, STADA and Alvotech announced the launch of biosimilar ustekinumab Uzpruvo® across the majority of European countries. This was quickly followed by Sandoz announcing the European launch of Pyzchiva® on 25 July 2024.